Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Long-Term Deferred Tax (2022)

Spyre Therapeutics' Long-Term Deferred Tax history spans 1 years, with the latest figure at $566000.0 for Q4 2022.

  • For Q4 2022, Long-Term Deferred Tax changed N/A year-over-year to $566000.0; the TTM value through Dec 2022 reached $566000.0, changed N/A, while the annual FY2022 figure was $566000.0, N/A changed from the prior year.
  • Long-Term Deferred Tax reached $566000.0 in Q4 2022 per SYRE's latest filing.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $566000.0 in Q4 2022 to a low of $566000.0 in Q4 2022.